Modelling US health equity impacts of emicizumab for severe haemophilia A: aggregate distributional cost-effectiveness analysis
Funding emicizumab treatments for PwSHA improves overall population health and reduces overall health inequities in the USA. Cost savings from the use of emicizumab free up important resources that can be leveraged to support other healthcare interventions, but decisions on how these funds are used have large consequences for equity.
Authors
- Randall Curtis (ORCID: https://orcid.org/0000-0002-6859-6432)
- Thomas Majda (ORCID: https://orcid.org/0009-0008-6331-0416)
- Janet S. Lee (ORCID: https://orcid.org/0000-0002-6812-6043)
- Stacey Kowal (ORCID: https://orcid.org/0000-0003-1981-8227)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1136/bmjopen-2025-103112
- Citations
- 1
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- University of Southern California
- F. Hoffmann-La Roche
- Genentech